Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Medical Sciences Division in Oxford University. The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University. Investors in OCB include Longwall Venture Partners LLP, Esperante BV, Ningbo My-BioMed Biotechnology Co.,Ltd., CancerRop Co. Ltd., and the University of Oxford. Oxford Cancer Biomarkers range of predictive biomarkers will help clinicians deliver personalised care to patients with colorectal cancer. The first to be launched is ToxNav, a 20 SNP germline assay that predicts individuals’ propensity to develop life-threatening adverse reactions from 5FU/capecitabine chemotherapy. OncoProg; a digital pathology test for the recurrence of Stage II tumours is already available in China. The company is working with academic partners to develop a population-based genome test for the lifetime risk of developing colorectal cancer.